Educational information, not financial advice or a personal recommendation. Not regulated by the FCA. Do your own research. Capital at risk.

Pfizer Inc. (PFE)

Healthcare Balanced

Pfizer is a global pharmaceutical giant that researches, develops, and manufactures medicines and vaccines to treat a wide range of human health conditions.

$25.01

Is Pfizer Inc. a good stock for a UK beginner?

The honest version: Pfizer is a global pharmaceutical giant that researches, develops, and manufactures medicines and vaccines to treat a wide range of human health conditions.

No rating · no target price · nothing for sale here
Price-18.4%
Priced in USD - as a UK investor your £ return also moves with the pound-to-dollar exchange rate, on top of the share price itself.
52-week range+2% past year
$25.01
Low $23.11High $28.75
Where today's price sits versus its past year - context, not a signal.
If you had put $1,000 into Pfizer Inc.
$816-18%

Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.

Market cap: The company's total value on the stock market - share price times the number of shares. Big = 'large-cap', small = 'small-cap'.
$142.54B
Avg volume: How many shares change hands on a typical day. Higher means it's easy to buy or exit without moving the price.
41.32M
Day range: The lowest and highest price the shares traded at during the latest day.
$24.67 – $25.18
52-week range: The lowest and highest the shares have traded over the past year - a sense of how wide the swings have been.
$23.11 – $28.75
P/E ratio: Price-to-earnings: the share price divided by yearly profit per share. Lower can mean cheaper; higher often means investors expect fast growth.
18.9
Dividend yield: The yearly dividend as a percentage of the share price - roughly the income you'd earn from dividends alone.
6.9%
Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down.
0.31
How bumpy is it?Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down. 0.31
Calm
Wild
Steadier than most

Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.

Why has it been moving?▼ -0% past week · ▲ +2% past year

Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.

The bull case

Breakthroughs in high-growth areas like oncology

The bear case

Failure to innovate and loss of patent protection on major drugs

What does Pfizer Inc. do?

Pfizer makes its money by discovering new drugs and selling them to healthcare providers and pharmacies worldwide. After a massive surge in demand for its pandemic-related products, the company is now focused on growing its core business through new drug launches and acquisitions. How successfully they can replace the revenue from their older, best-selling products with new treatments currently in their pipeline will decide a lot.

VQGMI
Factor profile

On our factor screen it looks strongest on value and income, and weakest on growth.

Value: How cheap the stock looks versus profits, sales and assets (higher = cheaper). 68Quality: How profitable and financially healthy the company is (higher = stronger). 54Growth: How fast revenue and earnings are growing (higher = faster). 25Momentum: How the share price has been trending recently (higher = stronger recent run). 39Income: The dividend income on offer and how sustainable it looks (higher = more/steadier). 54
Quick checks
What's strong
  • Extensive global distribution network
  • Strong history of paying dividends to shareholders
  • High gross margins indicating efficient production
What to watch
  • Growth screens low (25/100)
  • Patent expirations leading to loss of exclusivity
  • Strict government regulation on drug pricing
  • High costs and uncertainty associated with clinical trials

What do Pfizer Inc.'s numbers mean?

P/E
18.7
This shows how much you are paying for every pound of the company's recent annual profit.
Forward P/E
8.6
This compares the share price to the profit analysts expect the company to make over the next year.
Dividend yield
7.1%
This is the annual cash payout to shareholders as a percentage of the current share price.
Beta
0.3
This suggests the share price tends to be much less jumpy than the wider stock market.

How much money does Pfizer Inc. make?

Revenue and profit by quarter, and how much of each sale turns into profit.

RevenueNet income
$0$4.39B$8.78B$13.17B$17.56BQ1 25Q2 25Q3 25Q4 25Q1 26
Gross margin
74.8%
Net margin
11.8%
Return on equity
8.3%

Does Pfizer Inc. pay a dividend?

Yes - Pfizer Inc. currently pays a dividend of about 6.9% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.

When does Pfizer Inc. report earnings, and how did recent quarters go?

Pfizer Inc. is next scheduled to report on about 2026-08-04 - dates can move, and we don't predict results; this just tells you when to look.

Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.

ReportedExpected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number.Actual EPSvs expected
2026-05-05$0.72$0.75Beat +4%
2026-02-03$0.57$0.66Beat +16%
2025-11-04$0.63$0.87Beat +37%
2025-08-05$0.57$0.78Beat +36%
2025-04-29$0.67$0.92Beat +36%
2025-02-04$0.46$0.63Beat +37%

Across the last 6 quarters here, Pfizer Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.

See who else reports over the next two weeks →

Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.

More in Healthcare

Eli LillyWest Pharmaceutical Services, Inc.Incyte CorporationThe Cigna GroupZimmer Biomet Holdings, Inc.Moderna, Inc.Gilead Sciences, Inc.Regeneron Pharmaceuticals, Inc.

What are the scenarios for Pfizer Inc.?

An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.

$29$25$22today · $25▲ Bull · $27• Base · $25▼ Bear · $23in 1 yearILLUSTRATIVE · NOT A PREDICTION OR PRICE TARGET
Bull
+5% to +10%Stronger than expected sales of new drug launches
Base
-2% to +2%Steady performance in line with current market expectations
Bear
-5% to -10%Disappointing clinical trial results for key medicines

What are the pros and cons of Pfizer Inc.?

4bull points
6bear points

How many points the write-up makes each way — a balance check, not a score or verdict.

The bull case4
  • Extensive global distribution network
  • Strong history of paying dividends to shareholders
  • High gross margins indicating efficient production
  • Lower volatility compared to the broader market
The catch3
  • Recent decline in annual earnings
  • Heavy reliance on the success of new drug development
  • Significant competition from other pharmaceutical firms
Key risks3
  • Patent expirations leading to loss of exclusivity
  • Strict government regulation on drug pricing
  • High costs and uncertainty associated with clinical trials
What would flip the thesis

The write-up's own warning lights — if these start happening, the case above changes.

Confidence: medium · data: USD · flags: none · Charts by TradingView Lightweight Charts™
Found this useful? The Almanac is free and ad-free - a coffee keeps it that way.Support →

Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →

This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.

Figures as of 2026-08-01. Prices may be delayed and numbers can go stale - always double-check before acting.